Indications and uses
Fem pH is indicated as adjunctive therapy in those cases where restoration and maintenance of vaginal acidity is desirable.
Fem pH is indicated as adjunctive therapy in those cases where restoration and maintenance of vaginal acidity is desirable.
The usual dose is one applicator full, administered intra-vaginally, morning and evening. Duration of treatment may be determined by the patient's response to therapy. Each tube has a tamper evident seal at the opening of the tube. Replace cap after each use. To fill applicator screw applicator clockwise onto the tube. Squeeze tube forcing Fem pH jelly into barrel until it is full. Then unscrew applicator counter-...
Rx Only
Fem pH Vaginal Jelly is a bland, non-irritating water dispersible, buffered acid jelly for intravaginal use. Fem pH is classified as a Vaginal Therapeutic Jelly. Fem pH contains 0.9% glacial acetic acid (C2H402) and 0.025% oxyquinoline sulfate (C18H16N206S) compounded with glycerin, lactic acid, poly ethylene glycol 4500 and purified water. Fem pH is formulated to pH 3.8-4.3 and is adjusted using 1 N potassium hydroxide.
Fem pH acts to restore and maintain normal vaginal acidity through its buffered action.
Fem pH is indicated as adjunctive therapy in those cases where restoration and maintenance of vaginal acidity is desirable.
None known.
No serious adverse reactions or potential safety hazard have been reported with the use of Fem pH.
No special care is required for the safe and effective use of Fem pH.
No incidence of drug interactions has been reported with concomitant use of Fem pH and any other medication.
The monitoring of vaginal acidity (pH) may be helpful in following the patient's response. (The normal vaginal pH has been shown to be in the range of 4.0 to 5.0)
No long-term studies in animals have been performed to evaluate carcinogenic potential.
Animal reproduction studies have not been conducted with Fem pH. It is not known whether Fem pH can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Fem pH should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fem pH is administered to a nursing woman.
Occasional cases of local stinging and burning have been reported.
The usual dose is one applicator full, administered intra-vaginally, morning and evening. Duration of treatment may be determined by the patient's response to therapy. Each tube has a tamper evident seal at the opening of the tube. Replace cap after each use. To fill applicator screw applicator clockwise onto the tube. Squeeze tube forcing Fem pH jelly into barrel until it is full. Then unscrew applicator counter-clockwise to remove from tube. Lie on your back with knees drawn up. Hold filled applicator by the barrel and gently insert it into the vagina as far as it will comfortably go. Press plunger to empty the contents. Keep the plunger depressed and remove the applicator from vagina. After each use pull applicator apart and wash with warm soapy water, rinse well, dry and reassemble.
50g Tube (NDC 00813-0799-55) with Fem pH applicator.
Keep this and all medication out of the reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
Store at controlled room temperature 59°-86°F (15°-30°C)
Directions for using Fem pH applicator.

Each tube has a tamper evident seal at the opening of the tube. Replace cap after each use.
To fill applicator screw applicator clockwise onto the tube. Squeeze tube forcing Fem pH jelly into barrel until it is full. Then unscrew applicator counter-clockwise to remove from tube. Lie on your back with knees drawn up. Hold filled applicator by the barrel and gently insert it into the vagina as far as it will comfortably go. Press plunger to empty the contents. Keep the plunger depressed and remove the applicator from vagina. |
After each use pull applicator apart and wash with warm soapy water, rinse well, dry and reassemble.

NDC 00813-0799-55
Rx Only
Fem pH™
Therapeutic Vaginal Jelly
Net Weight 50g
(1.66 oz.)
pharmicsINC
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 543873 | acetic acid 0.9 % / oxyquinoline sulfate 0.025 % Vaginal Gel | PSN | 9 |
| 1243480 | fem pH 0.9 % / 0.025 % Vaginal Gel | PSN | 9 |
| 1243480 | acetic acid 0.009 MG/MG / oxyquinoline sulfate 0.00025 MG/MG Vaginal Gel [Fem pH] | SBD | 9 |
| 543873 | acetic acid 0.009 MG/MG / oxyquinoline sulfate 0.00025 MG/MG Vaginal Gel | SCD | 9 |
| 543873 | acetic acid 0.9 % / oxyquinoline sulfate 0.025 % Vaginal Gel | SY | 9 |
| 1243480 | Fem pH (acetic acid 0.9 % / oxyquinoline sulfate 0.025 % ) Vaginal Gel | SY | 9 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| f52be47f-7aa7-46c0-b1fa-50c18dd50206 | Product name | 1 | 20201029 |
| 444b3e50-f226-46ef-bfca-2e7035d140cd | Product name | 1 | 20190611 |
| 7cda52fc-125f-421c-8fea-bc1974370c49 | Product name | 2 | 20180703 |
| 48747306-602a-42cc-957b-5b0c69158eee | Product name | 1 | 20180604 |
| 597b1cfd-7b31-5048-62be-ca5cd740da2f | Product name | 1 | 20140508 |
| db5ebcdb-b6ae-21cd-4dc5-76cd84b5578b | Product name | 1 | 20140508 |
| ec2149b3-5c6d-5344-f757-c86411073075 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 0813-0799-55 | 2024-07-30 | C162847 | 48780-1 | 9d75b9d0-4846-f424-e053-dadaa90a57ce | Fem pH™ Therapeutic Vaginal Jelly |
| 0813-0799-55 | 2024-01-30 | C162847 | 48780-1 | 9d75b9d0-4846-f424-e053-dadaa90a57ce | Fem pH™ Therapeutic Vaginal Jelly |
| 0813-0799-55 | 2020-09-29 | C162847 | 48780-1 | 9d75b9d0-4846-f424-e053-dadaa90a57ce | Fem pH™ Therapeutic Vaginal Jelly |
| 0813-0799-55 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4846-f424-e053-dadaa90a57ce | Fem pH™ Therapeutic Vaginal Jelly |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0813-0799-55 | Fem pH | 50 g in 1 TUBE | JELLY | 50 | 9 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0813-0799-55 | GM - Gram | 0813-0799 | 224fc8a8-9eab-4914-ada5-56d63ec76f8a | 1 | 2013-06-04 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Acetic Acid | ACTIVE INGREDIENT | Q40Q9N063P | 1 | |
| Oxyquinoline sulfate | ACTIVE INGREDIENT | 61VUG75Y3P | 1 | |
| Acetic Acid | ACTIVE MOIETY | Q40Q9N063P | 1 | |
| Oxyquinoline | ACTIVE MOIETY | 5UTX5635HP | 1 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| Lactic Acid | INACTIVE INGREDIENT | 33X04XA5AT | 1 | |
| polyethylene glycol 4500 | INACTIVE INGREDIENT | TVH7653921 | 1 | |
| potassium hydroxide | INACTIVE INGREDIENT | WZH3C48M4T | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0813-0799 | 0813-0799-55 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| GLYCERIN | PDC6A3C0OX | IACT |
| LACTIC ACID | 33X04XA5AT | IACT |
| POLYETHYLENE GLYCOL 4500 | TVH7653921 | IACT |
| WATER | 059QF0KO0R | IACT |
| POTASSIUM HYDROXIDE | WZH3C48M4T | IACT |
| ACETIC ACID | Q40Q9N063P | ACTIB |
| OXYQUINOLINE SULFATE | 61VUG75Y3P | ACTIM |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| Lactic Acid | LACTIC ACID | 33X04XA5AT | INJECTION / INTRAVENOUS | 2232 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| polyethylene glycol 4500 | POLYETHYLENE GLYCOL 4500 | TVH7653921 | CAPSULE, EXTENDED RELEASE / ORAL | 53 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| Lactic Acid | LACTIC ACID | 33X04XA5AT | INJECTION / SUBCUTANEOUS | 10 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | MOUTHWASH / BUCCAL | 100 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / AURICULAR (OTIC) | 0.05 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, COATED / ORAL | 1 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| potassium hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | SOLUTION / INTRAVASCULAR | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| potassium hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | GEL / TOPICAL | 3 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| Lactic Acid | LACTIC ACID | 33X04XA5AT | GEL / TOPICAL | 30 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1800 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CLOTH / TOPICAL | 0.05 mg/mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| Lactic Acid | LACTIC ACID | 33X04XA5AT | SUPPOSITORY / VAGINAL | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| potassium hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | CREAM / VAGINAL | 3 mg | ||
| Lactic Acid | LACTIC ACID | 33X04XA5AT | CREAM / TOPICAL | 1 mg | ||
| Lactic Acid | LACTIC ACID | 33X04XA5AT | SUSPENSION / TOPICAL | 51 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| Lactic Acid | LACTIC ACID | 33X04XA5AT | AEROSOL, FOAM / TOPICAL | 11 mg | ||
| potassium hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | CAPSULE, LIQUID FILLED / ORAL | 154 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | ELIXIR / ORAL | 5621 mg | ||
| potassium hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | CAPSULE, DELAYED RELEASE / ORAL | 5 mg | ||
| Lactic Acid | LACTIC ACID | 33X04XA5AT | OINTMENT / TOPICAL | ADJ PH | ||
| potassium hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | SOLUTION / TOPICAL | 14.02 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| potassium hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | CAPSULE, EXTENDED RELEASE / ORAL | 0.07 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| Lactic Acid | LACTIC ACID | 33X04XA5AT | SOLUTION / ORAL | 192 mg | ||
| polyethylene glycol 4500 | POLYETHYLENE GLYCOL 4500 | TVH7653921 | CAPSULE / ORAL | 18 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DROPS / NASAL | 10 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / OPHTHALMIC | 3 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| potassium hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | CREAM / TOPICAL | 0.5 %w/w | ||
| potassium hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | INJECTION / INTRAVENOUS | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f28f9319-1a5b-276b-e053-2995a90a99bc | 77237c50-aeb5-44a0-a1e6-ce1551b49f75 | 2023-01-18 | Warnings, Adverse reactions | f28f9319-1a5b-276b-e053-2995a90a99bc 77237c50-aeb5-44a0-a1e6-ce1551b49f75 |
Adverse event summaries are temporarily unavailable. Other product information remains available.